Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mallinckrodt explores iNO as potential Covid-19 therapy
Details : Company published evidence suggesting a potential role of inhaled nitric oxide as a supportive measure in treating those patients infected with SARS-CoV-2 and having associated pulmonary difficulties.
Product Name : INOmax
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2020
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients
Details : Mallinckrodt has initiated a retrospective chart review study, titled "Nitric Oxide Treatment In COVID-19 Evaluation (NOTICE)" to collect real-world data on the use of INOmax® gas, for inhalation therapy in patients with respiratory complications associ...
Product Name : INOmax
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 11, 2020
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Massachusetts General Hospital
Deal Size : Undisclosed
Deal Type : Collaboration
Mallinckrodt to Fund Nitric Oxide Therapy Trial in Covid-19 Patients
Details : Mallinckrodt's support to Massachusetts General Hospital includes providing funding as well as INOmax® (nitric oxide) gas, for inhalation, to facilitate the study.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 30, 2020
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Massachusetts General Hospital
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study to investigate antiviral activity and improvement in oxygenation and pulmonary arterial pressure in patients suffering from COVID-19 got clearance from Health Canada.
Product Name : INOmax
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 04, 2020
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Corticotropin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Acthar on Everyday Life of Participants With Severe Keratitis
Details : Undisclosed
Product Name : Acthar
Product Type : Hormone
Upfront Cash : Inapplicable
November 19, 2019
Lead Product(s) : Corticotropin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : University of British Columbia
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2018
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : University of British Columbia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Chris Miller
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 06, 2017
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Chris Miller
Deal Size : Inapplicable
Deal Type : Inapplicable